We at KMC Clinic always try to update positive developments during the Covid pandemic and news about the effectiveness of vaccines is one of them.
Sinovac Biotech's COVID-19 vaccine candidate has shown the efficacy of 91.25% in Turkey, officials said, reporting the latest results of clinical trials of the Chinese-developed shot beyond China. The news comes after Brazil's Butantan Institute said CoronaVac's efficacy is above the required 50% mark but postponed announcing full results of trials in the South American nation for up to 15 days, at the company's request. Indonesia is also conducting Phase 3 trials of the Chinese-developed candidate.
In Turkey, 7,371 volunteers have participated in the trials so far, and data from 1,322 volunteers were used in the efficacy study. Only three volunteers reported positive PCR tests for COVID-19 out of the 752 who had been administered CoronaVac. Just one of them showed mild symptoms. Among the 570 volunteers who were administered a placebo, 26 later tested as positive for COVID-19. Clinical trials will continue until the study reaches 40 people showing positive PCR test results.
In another report, Sinovac Biotech’s Covid-19 vaccine, CoronaVac, has reportedly passed the 50% threshold for efficacy and demonstrated its effectiveness in late-stage trials carried out in Brazil. Scientists tracking the development of the vaccine expect it to have efficacy that is similar to other vaccines for Covid-19 that demonstrated an efficacy of 95% in trials.